fexinidazole Report issue

Small molecule Orphan Drug FDA Approved FDA Priority Review FDA
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Fexinidazole is a medication used to treat African trypanosomiasis caused by Trypanosoma brucei gambiense. It is effective against both first and second stage disease. Also a potential new treatment for Chagas disease, a neglected tropical disease that affects millions of people worldwide. It is taken by mouth.   Wikipedia

Chemistry

  • SMILES: CSc1ccc(OCc2ncc([N+](=O)[O-])n2C)cc1
  • InChIKey: MIWWSGDADVMLTG-UHFFFAOYSA-N
  • Mol. Mass: 279.32
  • ALogP: 2.63
  • ChEMBL Molecule:
    fexinidazole  
More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Alternative names

fexinidazole | hoe 239

Organizations (10)

Research & Development (9)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (7)

Approved Indications (1)


 

Trypanosomiasis, African (approved 2021)

Experimental Indications - Clinical Trial Phases 1-4 (7)


 

Chagas Disease (Phase 2)

Healthy Volunteers (Phase 1)

Leishmaniasis, Visceral (Phase 2)

Liver Diseases (Phase 1)

Sleep Disorders, Intrinsic (Phase 3)

Trypanosomiasis (Phase 3)

Trypanosomiasis, African (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 13
  • # of Trial Organizations: 9

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue